Article

What Should Specialty Pharmacists Know About the REVERCE Clinical Trial?

Conference|Gastrointestinal Cancers Symposium

Kohei Shitara, MD, Department of Gastrointestinal Oncology of National Cancer Center Hospital East, Japan, discusses the importance of the REVERCE clinical trial for specialty pharmacists.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Cardiovascular disease doctor or cardiologist holding red heart in clinic or hospital exam room office for csr professional medical service, cardiology health care and world heart health day concept - Image credit: Chinnapong | stock.adobe.com
Image credit: AwieDarwis | stock.adobe.com
Image credit: viperagp | stock.adobe.com
Related Content
Pharmaconutrition in Practice: How Pharmacists Can Lead the Way in Patient Nutrition and Wellness
July 10th 2025

Pharmaconutrition in Practice: How Pharmacists Can Lead the Way in Patient Nutrition and Wellness

Aislinn Antrim, Managing Editor
Pharmacy Times, Pharmacy Focus Oncology Edition
June 27th 2025

Allen's Story: The Promising Potential of Intratumoral Immunotherapy

Alexandra Gerlach, Associate Editor
ATOPP 2025: Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, FAPO, Highlights Must-See Sessions
July 9th 2025

ATOPP 2025: Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, FAPO, Highlights Must-See Sessions

Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, FAPO Alana Hippensteele, Lead Editor
S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk
June 3rd 2025

S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk

Alexandra Gerlach, Associate Editor
Steroids -- Image credit: Cozyta | stock.adobe.com
July 9th 2025

Steroid Use During ICI Treatment Lessens Effectiveness in Patients With NSCLC

Gillian McGovern, Associate Editor
Highlights From NLA 2025: Early LDL-C Reduction and Emerging Therapies
July 9th 2025

Highlights From NLA 2025: Early LDL-C Reduction and Emerging Therapies

Jennifer D. Goldman, PharmD, CDE, BC-ADM, FCCP Alana Hippensteele, Lead Editor